Tag:
AstraZeneca
Latest Headlines
Latest Headlines
AstraZeneca's PhIII chief scouts for blockbuster deals as revenue slides
AstraZeneca today had another big round of dismal revenue numbers to explain today. With generic rivals tearing at some of its key franchises, the pharma giant reported a 13% drop in revenue for the first quarter.
AstraZeneca, Aussie biotech outfit ally in $240M-plus discovery deal
AstraZeneca's partnership spree of the last two months has gone Down Under. As the company shrinks its internal research work force, AstraZeneca has tapped Brisbane, Australia-based Alchemia to hunt for small molecule drugs against multiple disease targets.
BIO: R&D execs say tweaks boost drug-development process
While the success rate in developing new disease treatments remains alarmingly low, a cadre of R&D executives from some of the world's biggest drug developers insisted at BIO that they've zeroed in on a number of ways to boost the chance a promising drug will actually reach patients.
AstraZeneca, Bind team up for cancer drug delivery
AstraZeneca and Bind Therapeutics have joined forces in the creation of a kinase inhibitor nanotech for treating cancer, part of Bind's Accurin line of delivery platforms.
AstraZeneca inks cancer deals with Bind Therapeutics, Horizon Discovery
AstraZeneca forged two oncology development deals on either side of the Atlantic.
Top AstraZeneca investor backs Soriot and his 'golden hello'
At least one big AstraZeneca shareholder isn't concerned about CEO Pascal Soriot's pay package.
AstraZeneca works both sides of the Atlantic in forging new cancer drug deals
While AstraZeneca's busy business development team was fashioning a new discovery deal with Bind Therapeutics in Cambridge, MA, it was also polishing a pact in the other Cambridge.
AstraZeneca and Boston biotech unite to blast cancer with a nanotech drug
The drug giant, which is in the process of renovating its R&D wing, has hired on the crafty Cambridge, MA-based biotech Bind Therapeutics to work on a kinase inhibitor nanotech drug for treating cancer.
Exec-pay brouhaha intensifies with thumbs-down shareholder vote at Actelion
They're not exactly carrying pitchforks and torches, but some activist shareholders are demanding satisfaction on executive pay.
Report: Antibiotics pipeline lackluster as resistance surges
As antibiotic resistance grows in the U.S. with the rise in increasingly deadly bacteria, nicknamed 'nightmare bacteria,' a new report has identified that only 7 drugs are in development to combat these superbugs.
